GlobeNewswire Clinical StudiesOriginal article
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
Phase 2positivelunsekimigPositive
AI Analysis
Summary
Sanofi announced that lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in phase 2 studies for asthma and chronic rhinosinusitis with nasal polyps. The positive data supports further development of the candidate in respiratory indications.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
Importance:7/10
Sentiment:
0.75
phase_2_successrespiratory_diseaseasthmaCRSwNPbispecific_nanobody
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on April 7, 2026 5:00 AM